QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer
Qiagen N.V. Common Shares (QGEN)
Last qiagen n.v. common shares earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corporate.qiagen.com/investor-relations
Company Research
Source: Business Wire
U.S. FDA approves therascreen BRAF V600E RGQ PCR assay as companion diagnosticTest will help identify patients eligible for treatment with the BRAF inhibitor, BRAFTOVI, which the FDA has approved for use in combination with ERBITUX® (cetuximab) in adults with previously treated metastatic colorectal cancer with a BRAF V600E mutation GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced launch of its novel therascreen® BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) following U.S. Food and Drug Administration (FDA) approval as a companion diagnostic to the BRAF inhibitor, BRAFTOVI® (encorafenib), which the FDA has approved for use in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.Colorectal cancer is the third most common type of cancer, and approximately 150,000 patients
Show less
Read more
Impact Snapshot
Event Time:
QGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QGEN alerts
High impacting Qiagen N.V. Common Shares news events
Weekly update
A roundup of the hottest topics
QGEN
News
- QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth [Yahoo! Finance]Yahoo! Finance
- QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable GrowthBusiness Wire
- Qiagen (NYSE:QGEN) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=QGEN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> froMarketBeat
- Qiagen N.V. (NYSE:QGEN) is a favorite amongst institutional investors who own 82% [Yahoo! Finance]Yahoo! Finance
- Qiagen (NYSE:QGEN) had its "hold (c)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
QGEN
Earnings
- 11/4/25 - Beat
QGEN
Sec Filings
- 1/9/26 - Form 25-NSE/A
- 1/8/26 - Form 25-NSE
- 12/22/25 - Form 6-K
- QGEN's page on the SEC website